Education & GREAT Committee GREAT... · 19-Sep-2019 GCIG Session 21-Sep-2019. Education Committee ASGO Keiichi Fujiwara ASGO 2019 in Incheon, ... content is including the stopping

Education & GREAT

Committee

May 28, 20208:00 am EDT

GCIG Spring Meeting

GCIG Spring Meeting

Education & GREAT Committee

Agenda

• Approval of Report Berek

• IGCS & ASGO Fujiwara

• CCRN McCormack

• ESGO Ray-Coquard

• Patient Advocacy Chavez-Blanco

• Young Investigators Poveda

• PARSGO Sehouli

• WHO & NCI Trimble

Education Committee

IGCS

Keiichi Fujiwara

IGCS 2019 Rio De Janeiro

GCIG/CCRN/BrGOG/LatainAmerica

Meeting

19-Sep-2019

GCIG Session

21-Sep-2019

Education Committee

ASGO

Keiichi Fujiwara

ASGO 2019 in Incheon,

South Korea

GCIG Session 12-Oct-2019

Keiichi Talked about GCIG

and CCRN

Yusuke talked about the importance of

Harmonization in GCIGNoriko discussed the importance of

Research Nurse

Education Committee

GREAT Initiative

GCIG/CCRN/IGCS

Mary and Ted at the Presidential Plenary

For Cervical Cancer Initiative

CCRN & COVID

5th annual symposium scheduled for Da

Nang 22-23 Feb 2020

According to the Official Letter No. 545/UBND-VHXH on

February 1, 2020 of the Danang People's Committee announced

about the prevention and control of acute respiratory infections

caused by new strains of Corona virus in festive activities. The

content is including the stopping all the festivals and the

symposiums

• 20 papers in IJGC in 2015

– Between 5 to 40 citations per year since 2015

• New proposal:

– Joint-venture with ESGO

• Co publication of the new version

→ Smartphone application

– Actions

• 2 batchs of 10 guidelines

• identification of the 2 co-coordinators by

guidelines

• To define a realistic agenda (2019 to 2021)

• To define rules of publications

Updated GCIG/ESGO guidelines

Isabelle Ray-Coquard & Jonathan

Ledermann

List of Coordinators and co

coordinators

Coordinator Group Co-Coordinator Group

Uterine carcinosarcoma Ketta Lorusso Y MITO Ronnie Shapira-Frommer ISGO

Uterine LMS Jae-Weon Kim Y KGOG Ana Oaknin GEICO

Sex cord tumour Isabelle Ray Coquard Y GINECO Philipp Harter AGO

Germ Cell tumour Nicoletta Colombo MaNGO Oleysa Solheim NSGO

Cancerized teratoma Ros Glasspool SGCTG Christian Marth A-AGO

Ovarian small cell carcinoma Clare Scott ANZGOG Patricia Pautier GINECO

Mucinous carcinoma Jonathan Ledermann Y NCRI Jubilee Brown GOG-F

Ovarian clear cell carcinoma Antonio Gonzales Y GEICO Keiichi Fujiwara GOTIC

Trophoblastic diseases Michael Seckl ISSTD Leon Massuger EORTC

Low grade serous carcinoma David Gershenson Y GOG-F Charlie Gourley SGCTG

1st Round 2018 - 2019

Already presented and validated in 2019 (GCIG meeting in June and

Oral presentation at ESGO meting in Athens)

Smartphone application is underway for

- SCT

- GCT

- Mucinous

- LGSC

- OCCC

- …

List of Coordinators and co

coordinators

Coordinator Group Co-Coordinator Group

Non Squamous Vulva & Vagina Malignancies C Marth Y Aus-AGO M Leito NRG/GOG

Clear Cell Carcinoma of the Uterine Corpus

and Cervix D Tan Y Singapore GOG M Mc Cormack NCRI

Carcinoid Tumors of the Ovary E Gomez Y GICOM C Zamagni MITO

Low grade endometrial stromal sarcoma F Amant Y EORTC/GCG L Ceppi MANGOHigh Grade Endometrial and undifferentiated

Sarcoma A Oza PMH-C P Pautier GINECO

Papillary serous carcinoma of uterusK Takehara

S Sagae Y JGOG B Monk GOG F

Adenosarcomas of uterus M Friedlander Y ANZGOG R Ambrust NOGGO

Glandular carcinoma of cervix M Plante Y CCTG J Liu Shangai GOG

Borderline Ovarian tumors P Harter Y AGO C Lok DGOG

Small Cell Carcinoma of the Cervix (SCCC) O Solheim Y NSGO D Cibula CEECOG

2nd Round 2019 -

2020

Tasks & Organisation

• Coordination of new GCIG/ESGO guidelines for rare

tumors

• 2 chairs + 8/12 experts from each groups (designed by

each group)

• 1 or 2 pathologist from different groups for each

guidelines

• 1 methodologist from ESGO (François Planchamp for

bibliography research and design)

Where we are by topics

0 50 100 150 200 250 300

Non Squamous Vulva & Vagina Malignancies

Clear Cell Carcinoma of the Uterine Corpus and Cervix

Carcinoid Tumors of the Ovary

Low grade endometrial stromal sarcoma

High Grade Endometrial and undifferentiated Sarcoma

Papillary serous carcinoma of uterus

Adenosarcomas of uterus

Glandular carcinoma of cervix

Borderline Ovarian tumors

Small Cell Carcinoma of the Cervix (SCCC)

Different topics and activity

1st draft Pathology review Circulating in the working group Under review

Tasks & Organisation

• Coordination of new GCIG/ESGO guidelines for rare tumors

• 2 chairs + 8/12 experts from each groups (designed by each group)

• 1 or 2 pathologist from different groups for each guidelines

• 1 methodologist from ESGO (François Planchamp for bibliography research

and design)

• Agenda 2nd round:

– To finalize the Initial draft during summer

– To circulate within all groups before October

– Final draft to be presented at the next GCIG meeting (Autumn 2020)

– Oral presentation in an International congress ? Where/When?

– Publication paper for all the guidelines?

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Best Practices for Patient Advocacy

and Clinical Trials

GCIG Harmonisation Committee

Update

ADRIANA CHÁVEZ-BLANCO,DVM.Gynecologic Cancer InterGroup

Cervix Cancer Research Network (GCIG CCRN)Co-ordinator, Latin América & CCRN Sites.

GCIG Education Committee, Spring Meeting May 28, 2020



Best Practices for Patient Advocacy and Clinical Trials

A GCIG Harmonisation Committee Initiative

Objective:

✓ How (and if) GCIG groups involve patients into their activities

✓ Encourage advocacy groups to join their GCIG groups

✓ Creation of an Advisory Panel

✓ Development of Templates

GCIG Education Committee Spring Meeting May 28, 2020



Best Practices for Patient Advocacy and Clinical Trials

(cont.)

❖ Survey

To provide feedback on the involvement of the patients of patients /

carers / patient advocates within each GCIG group

❖ Challenges

✓ funding,

✓ sustainability,

✓ proof of value,

✓ volunteers are sometimes very sick





GCIG Spring Meeting

Mentoring Young Investigators

Andrés Poveda,MD

GCIG Past-Chair

GCIG Spring Meeting – May 28th 2020, Virtual Meeting

GCIG Spring Meeting

• This program is a mandate of the GCIG Strategic Planning meeting

2018.

Objective:

• to foster the involvement of more junior investigators with GCIG.

• Set the basis to start this program in the 2019 GCIG Autumn

meeting (Athens).


GCIG Strategic PlannIng Meeting 2018.

SUMMARY

Definition of Young Investigators:

After discussion of the strategic planning meeting definition of “junior

investigator”, the Executive Committee agreed that, for these GCIG

purposes, a Junior Investigator is:

a) a trained medical, gynecologic, or radiation oncologist with a

defined primary focus in gynecologic cancers;

b) ideally within 10 years of completion of last training (clinical or

postdoctoral fellowship);

c) preliminarily experienced in phase 2/3 clinical trials in an active role

(study design, methodology, etc.), translational, or QoL/PRO

gynecologic cancer investigation.

d) an active member of a GCIG member group.

GCIG Fall Meeting – November 1st 2019, Athens


SUMMARY

Application in order to select the participants in this program:

• An application form to be sent to each GCIG group member, so

that each group can propose a candidate.

Proposals to be discussed:

• Consider groups creating their co-operative groups.

• Total number of participants to be set up (maximum 1 per GCIG group).

• Possibility to reserve a slot for competitive access to present at the

translational meeting based on the best abstract or abstracts.

• When new trials are discussed with industry, the inclusion of young

investigators in the group that performs the translational design, to be

negotiated.



SUMMARY

INVOLVEMENT

• Each member group should commit one of their 6 slots to a young

investigator each meeting.

• Each GCIG-badged study should have an identified young

investigator Co-PI.

• Mentorship of new groups should include identification of young

investigator(s) to participate in the mentoring process from the

outset.



SUMMARY

OPPORTUNITIES

• There should be a competitive process to identify young

investigator(s) for participation in Consensus and Brainstorming

conferences.

• Additional young investigators should be able to attend the GCIG

meetings through a competitive opportunity. GCIG will identify

additional observational “slots” for this participation. This opportunity

should have an “award” title for academic recognition, and be

funded (ideally; eg travel award sponsored by a GCIG pharma

member).



SUMMARY

OPPORTUNITIES

– A satellite session(s) targeted to the young investigators should be an

ongoing event.

– Teach key elements of trial design and execution: scientific

justification, design, statistics, PRO endpoints, data integrity,

international cooperation.

– Review of and assistance with ongoing trial design.

– Networking opportunities with GCIG member groups.

– Expansion into a one day trial design educational symposium at

next GCIG meeting (Athens, GCIG Autumn Meeting 2019 ).

GCIG Fall Meeting – May 2018, Chicago

GCIG Fall Meeting

SUMMARY

PROGRAM

GCIG Fall Meeting – November 1st 2019, Chicago

GCIG Fall Meeting

SUMMARY

ATTENDEES

- N: 16 YI + 5 Lecturers + 1 OPS

- REPRESENTED GROUPS:

- AGO-D, ASGO, BR-GOG, CEEGOG, GINECO, GOTIC, ISGOG, JGOG, KGOG,

KOLKATA-GOG, MANGO, MITO, SAKK, SGCTG, SGOG, Singapore-GCG.

- MAINLY LINKED TO PHASE-I AND TRASLATIONAL RESEARCH

– Networking opportunities with GCIG member groups.

– Expansion into a one day trial design educational symposium at

next GCIG meeting (CHICAGO, GCIG Spring Meeting 2020 ).


GCIG Fall Meeting

ACTIONS

- SURVEY/FEEDBACK FROM PARTICIPANTS

Feedback from the participants would be required.

– Has the first meeting of the YIP met your expectations?

– What do you expect as a result of participation in the full YI program?

– Please send us any suggestions that might help us to improve the program.

– SENT (by email) IN NOV 2019?

– NO ANSWERS

- Expansion into a one day trial design educational symposium

at next GCIG meeting (CHICAGO, GCIG Spring Meeting 2020 )

- CANCELLED.


GCIG Spring Meeting

PLANNING MEETING BY TC FEB 27,2020

SUMMARY

• Review:

– The October 31, 2019 Athens Young Investigator Program agenda was

reviewed.

– The Statistical Considerations presentation did not happen in Athens so will need

to be considered in the future.

– We had planned to survey the attendees to determine their interest but this did

not happen.

– This first session was a fairly general overview for the GCIG Member Group

Young Investigator delegates.


GCIG Spring Meeting


SUMMARY

• Plan for May 27, 2020 in Chicago:

– Attendees: many of the same YI delegates from GCIG Member Groups.

– Schedule: 2-3 hours at front end of meeting

– Curriculum Ideas:

– Start each session with a very brief overview – GCIG Mission and Vision – no more than 5 minutes

– Focus on clinical trial types pertinent to international collaboration and from the standpoint of investigator-initiated trials. Discuss good trial methodology (the gold standard) and discuss the components of trial design that can be problematic in the international setting.

• Suggest speakers.


GCIG Spring Meeting


SUMMARY


– Design of control:• What constitutes a control?

• Understanding of why historical controls no longer valid.

– Primary and Secondary endpoints:

– Trial types

– Statistical considerations – Harm Stats Committee involvement?

– Challenges of rare tumour trials – Clare Scott/Isabelle Ray-Coquard• GCIG-ESGO Rare Tumor guidelines and smart phone app


GCIG Spring Meeting


SUMMARY


• Presenters/presentations:– have speakers provide power point slides for distribution beforehand and that can stand

alone as a reference

– will look into cost and feasibility of taping presentations for reference

• Other:

– We will ask the GCIG-Foundation if we can offer to cover the cost of 1-night accommodation for the attendees to facilitate their earlier arrival to the GCIG Spring Meeting.


GCIG Spring Meeting

PROPOSALS

PROPOSALS FOR THE NEXT MEETING

FALL 2020, Leuven? (TBD)

• Online lectures.

• Ask the groups to keep the same person.

• Eclectic group, some close to the Nobel prize, some new

in the field

• Mentor, keep in touch, and lead them.

• 2 years Program, follow up of progress of participants.

Mentorship


WHO Global InitiativeUS

NCI

Global partnership

Update on global initiative:

1. Call for action by Dr. Tedros, May 2018

2. Resolution endorsed by WHO Executive Committee February

2020 and submitted to World Health Assembly May 2020;

encompasses primary prevention with HPV vaccination,

screening, treatment of precancer, treatment of invasive cancer,

palliative care, public education, strengthened data collection, and

expanded access to cancer services

3. No earmarked new money at WHO for the initiative; Clinton Health

Access Initiative (CHAI) has seconded a staff member to assist Dr.

Nono Simelela in her role as WHO coordinator for the initiative

4. WHO Geneva working with WHO regional offices on specific

countries (UN Joint Program 6, AFRO 8)


II

US

NCI

Global partnership

Update II:

1. International Atomic Energy Agency (Vienna) responsible for

helping countries with national cancer control planning, as well as

implementation of components related to cancer imaging, nuclear

medicine, and radiation therapy, including training of radiation

oncologists, radiologists, nuclear medicine physicians, medical

physicists, nurses, and technicians; recently signed MOU with

UNAIDS for joint work on cervical cancer

2. UNAIDS responsible for helping countries address cervical cancer

control in HIV+ populations

3. WHO International Agency for Research on Cancer responsible for

helping countries with cancer registries; working with WHO

Geneva on links to death registries, increased use of unique

personal identifiers, and strengthened health surveillance


III

US

NCI

Global partnership

Update III:

1. GAVI working on HPV vaccination in GAVI-eligible low-income

countries; WHO Pan-American Health Organization includes HPV

vaccines in its bulk-purchasing program for countries in the

Americas

2. US NCI and Gates Foundation funding definitive non-inferiority

phase III trial of one vs. two doses of Gardasil9® and Cervarix® in

Costa Rica

3. UNITAID working with CHAI and Expertise France to fund studies

of cervical cancer screening, triage, and treatment of pre-cancer in

subset of African and Central American countries

4. WHO Geneva working to develop educational materials for civil

society as well as evidence-based guidelines for screening, triage

and treatment of pre-cancer, treatment of invasive cancer,

symptom management, and palliative care


IV

US

NCI

Global partnership

Research and education:

1. WHO Geneva has set up HPV and cervical cancer research

working group, co-chaired by Drs. Doug Lowy (US NCI), Maribel

Almonte (WHO IARC), and Nathalie Broutet (WHO Geneva); staff

support: Ted Trimble and Doug Perin (US NCI)

2. Current HPV and cervical cancer research grants and contracts

are largely supported by the US National Institutes of Health (50%

US NCI, 25% other NIH institutes)

3. Educational needs include training, mentoring, and continuing

education for all disciplines required for management of women

with precancer and invasive cervical cancer

4. Research needs include implementation science across cancer

continuum as well as improvements in resource-sparing treatment

and symptom management for women with invasive cervical

cancer

Proposed cervical cancer

learning network

US

NCI

Global partnership

Objectives:

1. Improve access to and quality of cancer treatment, symptom

management, and palliative care for women with invasive cervical

cancer

2. Link mentors with expertise in cervical cancer management at

cancer centers in high-income and high-upper-middle income

countries with clinicians treating women with invasive cervical cancer

at high-volume sites in low- and low-middle income countries

3. Build capacity for and conduct prospective clinical research,

including prospective cohort studies, clinical trials, and implementation

science, to improve care for women with invasive cervical cancer

Cervical cancer learning

network: II

US

NCI

Global partnership

Core components:

1. GCIG and GCIG Cervical Cancer Research Network

2. GCIG member groups

3. Cancer centers in high- and high-middle income countries

4. Medical professional societies

5. World Health Organization

6. International Atomic Energy Agency

7. Industry

8. Civil society

9. Other?

Cervical cancer learning

network: III

US

NCI

Global partnership

Potential funders:

1. Global health development agencies in high-income countries?

2. NGOs?

3. Medical professional societies (for travel of mentors and

fellows/junior investigators)

4. US National Institutes of Health?

5. Industry-associated foundations?

Education & GREAT Committee

Thank you!

Documents

Education & GREAT Committee GREAT... · 19-Sep-2019 GCIG Session 21-Sep-2019. Education Committee ASGO Keiichi Fujiwara ASGO 2019 in Incheon, ... content is including the stopping